Pioneer in gastro-enterology and allergology since 1991, Novamil is present on all five continents and in over 60 countries with its innovative infant nutrition range. The company’s flagship brand Novamil is a leader and trend-setter in numerous markets and is commercialized in partnership with prominent pharmaceutical laboratories, achieving three-digit organic growth every few years.
Early on, Novamil created new market segments by adding a pharma dimension to the infant nutrition space, creating the first formulas to prevent, manage and treat several gastro-intestinal problems. That is how the company created the first formula to manage colics, gas, and bloating1 in 1997. Thereafter, the laboratory continuously rolled out new inventions such as the first formula to regulate the intestinal transit and prevent constipation2, the first formula for infants suffering from both allergies and regurgitations3, the first vegetable formula to simultaneously eliminate hard and liquid stools4, the first thickened amino-acids formula5, and more.
Today, the R&D pipeline is crowded, with several new innovations coming to market every year. The efficacy of the Novamil range is demonstrated in over 50 clinical trials and studies on over 48.000 infants.
In every country, Novamil partners with a strategic ally to bring these novelties to market.
Some of our partners:
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |